Policy and Practice
Subscribe
Sign in
Home
Notes
Archive
About
How The FDA Remade Drug Development
My new article in Asterisk Magazine
Dec 23, 2025
•
Adam
14
2
2
Latest
Top
Discussions
FDA is asking for fewer trials. That might be the right call.
How clinical trial progress - and changing economics - made the two-trial standard harder to defend
Dec 11, 2025
•
Adam
15
6
10
Why clinical trials are inefficient. And why it matters.
If we want to accelerate biomedical progress, we need to understand the root causes of clinical trial inefficiency.
Oct 14, 2025
•
Adam
13
6
Risk-based regulation is vague regulation
And vague regulation breeds safetyism
Sep 25, 2025
•
Adam
10
1
3
The Badness Police
A Theory of Regulation
Sep 17, 2025
•
Adam
11
1
3
A vision for clinical trial abundance
What does clinical trial abundance look like? And what still stands in our way?
Jul 24, 2025
•
Adam
5
1
The collapse of the FDA
FDA's power comes from its reputation. What happens when that reputation is gone?
Jul 11, 2025
•
Adam
7
1
Thoughts on FDA's New Commissioner's Priority Review Voucher Program
We need better ways to promote the development of new drugs. Will this help?
Jun 27, 2025
•
Adam
2
See all
Policy and Practice
Exploring innovation in health and medicine, and the institutions, incentives, and infrastructure that drive it.
Subscribe
Policy and Practice
Subscribe
About
Archive
Sitemap
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
